chodilator.7 After A-receptors were further subdivided into /1-and 32-receptors,8 more selective inhaled 02-agents were developed, including albuterol, bitolterol, fenoterol, metaproterenol, pirbuterol, salmeterol, terbutaline, and others. Albuterol became the most popular 32-agonist in this country. Today, both inhaled d-agonists and anticholinergics enjoy widespread use for improving airflow and reducing the symptom complex in patients with COPD.
Seven studies have compared the concurrent use of ipratropium and albuterol delivered by a metereddose inhaler.9 The efficacy of the combination exceeded that of each agent alone in five of these trials, but not in two. 9 All of these studies can be criticized by small numbers resulting in poor statistical power. For these reasons, an extensive, long-term (85-day) multicenter trial was conceived as the Combivent Study. Clinical researchers from 24 centers participated. The study design and conduct has been reported elsewhere.9
RESULTS
A total of 534 patients were recruited. The demographic and baseline characteristics within each treatment group, ie, combined ipratropium with al- buterol, and each agent separately, are presented in Table 1 , which is adapted from the original publication. 9 The total number of patients who were randomized and treated, those withdrawn for adverse effects, and those completing all test days are presented in Table 2 . Table 3 presents the mean FEV1 and baseline values on test days. Figure 1 presents the improvement over baseline in FEV1 on test days 1, 29, 57, and 85 of each agent used alone and the combination. The combination was superior to each individual agent, as observed in the figures. These differences are statistically significant as summarized in Table 4 , which is reproduced from the original article. Similar changes were observed in forced vital capacity (FVC), as illustrated in Figure 2 . Peak expiratory flow rate (PEFR) did not change during the 12-week treatment period in all three study groups. Both PEFR baseline and PEFR responses were comparable in these treatment groups. Mean forced expiratory flow during the middle half of FVC (FEF25-75%) showed changes similar to FEV1 and FVC. These data are not presented.
The physicians' global evaluations of patient symptomatic responses, done without knowledge of allocation to treatment group, yielded significantly better mean scores for patients in the combination group than for the other two groups on days 15 and 29, but the differences were relatively small. The patient's COPD symptoms' scores did not change over time and did not differ among the treatment groups on average. The symptom scores were of mild severity. Only seven (3.8%) patients in the combination group, compared with 11 (6.1%) patients in the ipratropium group and 18 (10.4%) in the albuterol group needed to add an additional systemic oral steroid to the regimen because of worsening symptoms. The total number of patient days of increased steroid use was 37 (0.25%) for those taking the combination, 66 (0.47%) for those taking ipratropium, and 94 (0.68%) for those taking albuterol.
The safety profile was similar in all study groups. Two patients died during the study, both of them in the combination group. One was a 75-year-old white man who died of the complications of atherosclerotic heart disease. The other was a 60-year-old black man with a history of myocardial infarction; his death was believed to be due to COPD and not to the study medications that he had used successfully for 3 months prior to death. Additional, insignificant adverse events are detailed in the original report.9 DISCUSSION The results of this study show that the combination of an anticholinergic bronchodilator, ipratropium, with a widely used 3-agonist, albuterol, produced peak effects superior to either agent alone. The area under the response curves was increased for up to 4 h for the combination, compared with lesser responses for each agent alone. Improved airflow or volume beyond 4 h was not significantly different between the study groups. The advantages of using a combination with improved clinical efficacy are many. These include the following: (1) chial hyperreactivity (:-agonists); (2) ,3-agonists work throughout both the central and peripheral conducting airways, whereas anticholinergic bronchodilators are most effective in the central connecting airways; (3) convenience of using both agents at one time; (4) potential cost savings of using both agents in the same metered-dose inhaler; and (5) the possibility of avoiding (-agonist overuse by virtue of the effectiveness of the concomitant anticholinergic agent. The apparent lack of a perception of better symptomatic relief from the combination compared with each agent alone by the patients may be due to the mild level of symptoms and/or the use of other bronchodilating agents or corticosteroids that were continued at the patient's usual dose, except for short increases in steroid therapy for limited periods.
It has been proposed that the long-term use of inhaled d-agonists to deal with nonspecific bronchial hyperreactivity might alter the rate of decline in FEV1.10 However, this topic has created controversy.11 The recently completed Lung Health Study, which employed ipratropium vs placebo, demonstrated a bronchodilator effect throughout the 5-year study, but the bronchodilator effect was lost when ipratropium was not given.'2 Thus, there was no alteration in baseline FEV, following 5 years of inhalation of the inhaled anticholinergic. It is possible that different results would have been obtained had a [-agonist been studied. In addition to a bronchodilating effect, d-agonists have the ability to improve mucociliary clearance and stimulate surfactant production. These same qualities are not available from an anticholinergic bronchodilator.
Thus far, to our knowledge, no study has evaluated the effect of the combination of anticholinergic and A-agonists on the rate of decline of FEV, in both patients who continued to smoke and those who were successful in stopping smoking.
The final utility of a combination 3-agonist and anticholinergic in the long-term maintenance management of patients with moderately severe COPD remains to be determined by longitudinal studies.
The present study shows superior efficacy of the combination, no additive side effects, and excellent patient acceptance. Thus, this study suggests that the combination product may be useful as an alternative to either anticholinergics or 3-agonists used separately in patients with COPD.
